Coadministration of ledipasvir (90 mg once daily), sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily) and tenofovir alafenamide (10 mg once daily) was studied using the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet. There was no effect on the AUC, Cmax or Cmin of emtricitabine, nor on the AUC and Cmax of tenofovir alafenamide. Ledipasvir AUC, Cmax and Cmin increased by 79%, 65% and 93%, respectively. Sofosbuvir AUC and Cmax increased by 47% and 29%, respectively. The AUC and Cmin of GS-331007 (sofosbuvir metabolite) increased by 48% and 66%, but there was no change in Cmax. Coadministration of ledipasvir (90 mg once daily), sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily) and tenofovir alafenamide (25 mg once daily) was studied using the emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet. There was no effect on ledipasvir AUC, Cmax and Cmin, nor on sofosbuvir AUC and Cmax, nor on GS-331007 (sofosbuvir metabolite) AUC, Cmax and Cmin, nor on emtricitabine AUC, Cmax and Cmin. Tenofovir alafenamide AUC increased by 32% but there was no change in Cmax. No dose adjustment of ledipasvir or sofosbuvir is required. For HIV-1 treatment, dose Descovy according to the concomitant antiretroviral.

Based on drug interaction studies conducted with the components of Descovy, no clinically significant drug interactions have been either observed or are expected when Descovy is combined with ledipasvir/sofosbuvir.